Medicines from the GLP-1 group, including Ozempik and Vegovi, have experienced a real boom in recent years, and their popularity has increased in particular due to their effect on reducing body weight, which has led to a sharp increase in demand.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Medicines from the GLP-1 group, including Ozempik and Vegovi, have experienced a real boom in recent years, and their popularity has increased in particular due to their effect on reducing body weight, which has led to a sharp increase in demand.